echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Xiamen issues measures to support the R & D and production of new coronavirus biomedicine

    Xiamen issues measures to support the R & D and production of new coronavirus biomedicine

    • Last Update: 2020-02-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [policies and regulations of pharmaceutical network In order to novel coronavirus novel coronavirus, Xiamen has been combining with the local biomedical enterprises' basic advantages in diagnosis, epidemic prevention, elimination and protection in the field of new coronavirus, and encouraged relevant enterprises and research institutions to take urgent measures to speed up the innovation and development of the epidemic prevention and control products, and to enhance the ability to provide services for the front-line prevention and control The novel coronavirus has been released in Xiamen to support the development and production of new coronaviruses It is reported that Xiamen has made efforts to boost R & D costs and advance R & D expenses in 6 aspects It encourages relevant enterprises and research institutions to take urgent measures to speed up the innovation, development and production of epidemic prevention and control products For example, in the aspect of accelerating the research and development of emergency products, the measures pointed out that the establishment of emergency science and technology projects should mobilize the strength of Xiamen universities, scientific research institutes, medical and health institutions and enterprises, support the research and development of emergency products with simple procedures, and strive for the rapid development of virus detection, prevention and control technologies and products in the short term At the same time, the measures point out that the emergency projects are exempt from expert review and are not included in the scope of the Municipal Science and technology plan projects In addition, Xiamen also increased efforts to cash in R & D subsidies in advance For biomedical enterprises that develop and produce epidemic prevention and control products, the subsidy for research and development in 2020 will be allocated in advance The first subsidy will be allocated from June to February, with the proportion increased from 60% to 80% To create the necessary conditions for the development of emergency products during the epidemic period of the enterprise, and for the qualified medical institutions to try out the in vitro products newly developed by the enterprise but without the registration certificate, the CDC will provide support for the product validation conditions in combination with the current epidemic emergency detection work In terms of accelerating the registration and approval of emergency products, Xiamen supports enterprises to enter the green channel for emergency review and approval of prevention and control products The novel coronavirus epidemic prevention and control directly related to the registration and certification of the second categories, third types of medical devices, and clinical or new drug certificate of vaccination products, on the basis of existing policies by increasing 100% reward In terms of expanding the production of emergency products, Xiamen encourages enterprises to expand their production capacity and intensify the production of mature emergency products with clear orders, production approvals or requisitions by urban government departments (I) reward 5% of the newly increased sales revenue during the epidemic period, up to 5 million yuan, and list the emergency products in the real estate industrial products catalogue of Xiamen (2) for enterprises applying to the bank for special loans for capital increase and production expansion during the epidemic period, priority shall be given to supporting enterprises to be listed in the list of national key enterprises of the national development and Reform Commission and the Ministry of industry and information technology, applying for preferential loans and special discount interest policies of the Ministry of Finance on epidemic prevention and control If they are not listed in the list of the state, support of 50% discount interest shall be given (3) coordinate the government guarantee company to increase the credit of the emergency product manufacturer For new secured loans obtained by related enterprises through guarantee companies during the epidemic period, the guarantee fee shall be charged in half It is understood that novel coronavirus pneumonia has occurred as the lead unit of Xiamen bio medicine and Health 100 billion industry chain Xiamen science and Technology Bureau, based on the industrial advantages and scientific research foundation of the in vitro diagnostic field, urgently launched the epidemic prevention and control emergency research and research special project, and promoted the pace of developing more than 10 diagnostic and testing kits, antibodies and equipment in the city   In addition, Li Qingge's team of Xiamen University has joined hands with Zhishan biology to successfully record and register the developed nucleic acid extraction reagent for new coronavirus, which can supply 42000 people to the market every week; the new coronavirus gene detection kit developed by Eide biology has donated more than 20 medical institutions with 15000 copies in total; the rapid detection system for new coronavirus nucleic acid developed by Anbang biology is applying for further development Access to the fast approval channel of the State Food and Drug Administration According to the introduction of relevant people, facing the national strategy of "healthy China", the biomedical and health industry has become one of the 100 billion industrial chain clusters that Xiamen focuses on Xiamen strengthened top-level design and path planning As early as 2003, it listed biomedical and health industry as a strategic emerging industry, and in 2013, it was listed as one of the 100 billion industrial chain groups Over the years, Xiamen has guided and supported leading enterprises in science and technology to increase their research and development of cutting-edge technologies and encourage them to become bigger and stronger It has not only produced a number of national and even global leading innovative products, but also cultivated a number of enterprises with strong competitiveness, promoting the rapid development of the city's biomedical industry  
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.